title: Cangrelor: Pharmacology, Clinical Data, and Role in Percutaneous Coronary Intervention.
abstract: In clinical trials that assessed the safety and efficacy of cangrelor during percutaneous coronary intervention (PCI), cangrelor was administered as a 30-μg/kg bolus followed by a 4-μg/kg/min infusion for at least 2 hours or the duration of the PCI, whichever was longer. Cangrelor is currently indicated as an adjunct to PCI to reduce the risk of myocardial infarction, repeat coronary revascularization, and stent thrombosis in patients who have not been treated with a P2Y12platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.
authors.affiliation: Division of Cardiovascular Diseases, Scripps Clinic, 9898 Genesee Avenue, Suite AMP-200, La Jolla, CA 92037, USA. Electronic address: price.matthew@scrippshealth.org.
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Price
mesh_terms: D000249:Adenosine Monophosphate / Q000008:administration & dosage / Q000031:analogs & derivatives*; D003324:Coronary Artery Disease / Q000601:surgery*; D006801:Humans; D007275:Injections, Intravenous; D062645:Percutaneous Coronary Intervention; D011183:Postoperative Complications / Q000517:prevention & control*; D058921:Purinergic P2Y Receptor Antagonists / Q000008:administration & dosage
chemical_list: D058921:Purinergic P2Y Receptor Antagonists; D000249:Adenosine Monophosphate; C117446:cangrelor
keywords: Cangrelor; Myocardial infarction; P2Y(12) receptor; Percutaneous coronary intervention; Stent thrombosis; Thienopyridine